PECAM1 and non-small cell lung carcinoma: Moreover, since CD31-labeled circulating endothelial cells serve as a predictor in anlotinib-treated non-small-cell lung cancer (38), this suggests that CD31 may be a marker for the response of UPS to anlotinib and toripalimab.